{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:02:06Z","timestamp":1790276526281,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hitachi Chemical Diagnostic systems Co., Ltd.","award":["207100000460"],"award-info":[{"award-number":["207100000460"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00774-021-01258-7","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T13:03:14Z","timestamp":1628168594000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system"],"prefix":"10.1007","volume":"40","author":[{"given":"Hajime","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minae","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichihiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-5372","authenticated-orcid":false,"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"1258_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429\u2013435","journal-title":"J Bone Miner Res"},{"key":"1258_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770\u2013774","journal-title":"Nature"},{"key":"1258_CR3","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/endo.143.8.8795","volume":"143","author":"T Shimada","year":"2002","unstructured":"Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179\u20133182","journal-title":"Endocrinology"},{"key":"1258_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng1358","volume":"36","author":"O Topaz","year":"2004","unstructured":"Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E (2004) Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579\u2013581","journal-title":"Nat Genet"},{"key":"1258_CR5","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541\u20133549","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR6","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1073\/pnas.1402218111","volume":"111","author":"VS Tagliabracci","year":"2014","unstructured":"Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, Koller A, Nizet V, White KE, Dixon JE (2014) Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci 111:5520\u20135525","journal-title":"Proc Natl Acad Sci"},{"key":"1258_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815166116","author":"Y Takashi","year":"2019","unstructured":"Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, Nangaku M, Abe M, Matsuhisa M, Kato S, Matsumoto T, Fukumoto S (2019) Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci. https:\/\/doi.org\/10.1073\/pnas.1815166116","journal-title":"Proc Natl Acad Sci"},{"key":"1258_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1210\/er.2017-00220","volume":"39","author":"Y Kinoshita","year":"2018","unstructured":"Kinoshita Y, Fukumoto S (2018) X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment. Endocr Rev 39:274\u2013291","journal-title":"Endocr Rev"},{"key":"1258_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"F Francis","year":"1995","unstructured":"Francis F, Hennig S, Korn B, Reinhardt R, de Jong P et al (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X linked hypophosphatemic rickets. Nat Genet 11:130\u2013136","journal-title":"Nat Genet"},{"key":"1258_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"KE White","year":"2000","unstructured":"White KE, Evans WE, O\u2019Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345\u2013348","journal-title":"Nat Genet"},{"key":"1258_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ng1905","volume":"38","author":"JQ Feng","year":"2006","unstructured":"Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310\u20131315","journal-title":"Nat Genet"},{"key":"1258_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ng1868","volume":"38","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Bastepe M, Benet-Pag\u00e8s A, Amyere M, Wagenstaller J, M\u00fcller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, J\u00fcppner H, Strom TM (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248\u20131250","journal-title":"Nat Genet"},{"key":"1258_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","volume":"86","author":"V Levy-litan","year":"2010","unstructured":"Levy-litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 Gene. Am J Hum Genet 86:273\u2013278","journal-title":"Am J Hum Genet"},{"key":"1258_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2010.01.006","volume":"86","author":"B Lorenz-Depiereux","year":"2010","unstructured":"Lorenz-Depiereux B, Schnabel D, Tiosano D, H\u00e4usler G, Strom TM (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267\u2013272","journal-title":"Am J Hum Genet"},{"key":"1258_CR15","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500\u20136505","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1258_CR16","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T (2009) Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Bone 45:814\u2013816","journal-title":"Bone"},{"key":"1258_CR17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, Padidela R, van\u2019tHoff W, Mao M, Chen C-Y, Skrinar A, Kakkis E, San Martin J, Portale AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987\u20131998","journal-title":"N Engl J Med"},{"key":"1258_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393","journal-title":"J Bone Miner Res"},{"key":"1258_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","author":"SM Jan de Beur","year":"2020","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO (2020) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"key":"1258_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235\u20131239","journal-title":"Bone"},{"key":"1258_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62:811\u2013816","journal-title":"Endocr J"},{"key":"1258_CR22","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87:4957\u20134960","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"1258_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","volume":"30","author":"Y Shimizu","year":"2012","unstructured":"Shimizu Y, Fukumoto S, Fujita T (2012) Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab 30:217\u2013221","journal-title":"J Bone Miner Metab"},{"key":"1258_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"327","author":"J Martin Bland","year":"1986","unstructured":"Martin Bland J, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327:307\u2013310","journal-title":"Lancet"},{"key":"1258_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2011.06.011","volume":"58","author":"JH Ix","year":"2011","unstructured":"Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA (2011) Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: The heart and soul study. Am J Kidney Dis 58:737\u2013745","journal-title":"Am J Kidney Dis"},{"key":"1258_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00404-020-05567-6","volume":"302","author":"F Saki","year":"2020","unstructured":"Saki F, Sadeghian F, Kasaee SR, Koohpeyma F, Ranjbar Omrani GH (2020) Effect of prolactin and estrogen on the serum level of 1,25-dihydroxy vitamin D and FGF23 in female rats. Arch Gynecol Obstet 302:265\u2013271","journal-title":"Arch Gynecol Obstet"},{"key":"1258_CR28","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren \u00d6, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, J\u00fcppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-Linked hypophosphatemia. N Engl J Med 348:1656\u20131663","journal-title":"N Engl J Med"},{"key":"1258_CR29","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1210\/jc.2005-2105","volume":"91","author":"EA Imel","year":"2006","unstructured":"Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055\u20132061","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/j.1523-1755.2005.00178.x","volume":"67","author":"JJ Kazama","year":"2005","unstructured":"Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120\u20131125","journal-title":"Kidney Int"},{"key":"1258_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1365-2796.2010.02262.x","volume":"268","author":"N Ito","year":"2010","unstructured":"Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T (2010) Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia: letter to the editor. J Intern Med 268:390\u2013394","journal-title":"J Intern Med"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-021-01258-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:08:35Z","timestamp":1642428515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-021-01258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s00774-021-01258-7","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NO, ST and HM are full-time employees of Minaris Medical Co., Ltd. However, the authors had full control of the findings, and the results were presented without supervision or interference from the sponsor of the work. All other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the Declaration of Helsinki, and procedures for healthy individuals and patients with chronic hypophosphatemia were approved by the institutional ethical board of Minaris Medical (Ref. 2016\/2#1 and 2016\/2#4) and the University of Tokyo Hospital (Ref. 2879-(7) and 2945-(12)), respectively.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}